Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics

Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Modern pathology 2022-10, Vol.35 (10), p.1411-1422
Hauptverfasser: Gisriel, Savanah D., Yuan, Ji, Braunberger, Ryan C., Maracaja, Danielle L.V., Chen, Xueyan, Wu, Xiaojun, McCracken, Jenna, Chen, Mingyi, Xie, Yi, Brown, Laura E., Li, Peng, Zhou, Yi, Sethi, Tarsheen, McHenry, Austin, Hauser, Ronald G., Paulson, Nathan, Tang, Haiming, Hsi, Eric D., Wang, Endi, Zhang, Qian-Yun, Young, Ken H., Xu, Mina L., Pan, Zenggang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1422
container_issue 10
container_start_page 1411
container_title Modern pathology
container_volume 35
creator Gisriel, Savanah D.
Yuan, Ji
Braunberger, Ryan C.
Maracaja, Danielle L.V.
Chen, Xueyan
Wu, Xiaojun
McCracken, Jenna
Chen, Mingyi
Xie, Yi
Brown, Laura E.
Li, Peng
Zhou, Yi
Sethi, Tarsheen
McHenry, Austin
Hauser, Ronald G.
Paulson, Nathan
Tang, Haiming
Hsi, Eric D.
Wang, Endi
Zhang, Qian-Yun
Young, Ken H.
Xu, Mina L.
Pan, Zenggang
description Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.
doi_str_mv 10.1038/s41379-022-01091-x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9926946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893395222002563</els_id><sourcerecordid>2664806804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhSMEokPhD7BAltiwCdh52ghVggooUiU2sLZubm4mrhJ7sJ2hs-WX4yGlPBZdWfL9zvE9Pln2VPCXgpfyVahE2aqcF0XOBVciv76XbURd8nQl6_vZhktV5qWqi5PsUQhXnIuqlsXD7KSs66ZI6k3242KZwbKR_I7C3vglMJlb2kI0e2I0DEswzuYdBOrZBH5L7F2ONE1sOsy70c3wmgHrTYjGYmRko4kH9t3EkS3WfFuI4WSsQbeDOLrJbQ0yHMEDRvJHFYbH2YMBpkBPbs7T7OuH91_OL_LLzx8_nb-9zLEu2pgLPqQ4opEddBJlW0NVNkDUCgRVK970UgLyXkkYKqz6FlupBGAHqIam4-Vpdrb67pZuph7Trh4mvfNmBn_QDoz-d2LNqLdur5UqGlU1yeDFjYF3KVmIejbh-BdgyS1BF01TSd5IXiX0-X_olVu8TfF00QqZsFYeqWKl0LsQPA23ywiujxXrtWKdKta_KtbXSfTs7xi3kt-dJqBcgZBGdkv-z9t32r5ZVZQq2JukCmjIIvXGE0bdO3OX_CeGEMou</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718480784</pqid></control><display><type>article</type><title>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Gisriel, Savanah D. ; Yuan, Ji ; Braunberger, Ryan C. ; Maracaja, Danielle L.V. ; Chen, Xueyan ; Wu, Xiaojun ; McCracken, Jenna ; Chen, Mingyi ; Xie, Yi ; Brown, Laura E. ; Li, Peng ; Zhou, Yi ; Sethi, Tarsheen ; McHenry, Austin ; Hauser, Ronald G. ; Paulson, Nathan ; Tang, Haiming ; Hsi, Eric D. ; Wang, Endi ; Zhang, Qian-Yun ; Young, Ken H. ; Xu, Mina L. ; Pan, Zenggang</creator><creatorcontrib>Gisriel, Savanah D. ; Yuan, Ji ; Braunberger, Ryan C. ; Maracaja, Danielle L.V. ; Chen, Xueyan ; Wu, Xiaojun ; McCracken, Jenna ; Chen, Mingyi ; Xie, Yi ; Brown, Laura E. ; Li, Peng ; Zhou, Yi ; Sethi, Tarsheen ; McHenry, Austin ; Hauser, Ronald G. ; Paulson, Nathan ; Tang, Haiming ; Hsi, Eric D. ; Wang, Endi ; Zhang, Qian-Yun ; Young, Ken H. ; Xu, Mina L. ; Pan, Zenggang</creatorcontrib><description>Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/s41379-022-01091-x</identifier><identifier>PMID: 35562413</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>13/1 ; 13/51 ; 38/32 ; 631/67/1990/291/1621/1915 ; 692/699/1541/1990/291/1621/1915 ; Aged ; Aged, 80 and over ; B-cell lymphoma ; Case reports ; CD20 antigen ; Chemotherapy ; Effusion ; Epstein-Barr virus ; Epstein-Barr Virus Infections - complications ; Herpesviridae Infections - complications ; Herpesvirus 4, Human ; Herpesvirus 8, Human ; HIV ; Human immunodeficiency virus ; Humans ; Laboratory Medicine ; Lymphocytes B ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Primary Effusion - diagnosis ; Lymphoma, Primary Effusion - pathology ; Medical prognosis ; Medicine ; Medicine &amp; Public Health ; Myc protein ; Pathology ; Pax5 protein ; Pleural cavity ; Primary effusion lymphoma ; Retrospective Studies ; Rituximab ; Targeted cancer therapy</subject><ispartof>Modern pathology, 2022-10, Vol.35 (10), p.1411-1422</ispartof><rights>2022 United States &amp; Canadian Academy of Pathology</rights><rights>The Author(s), under exclusive licence to United States &amp; Canadian Academy of Pathology 2022</rights><rights>2022. The Author(s), under exclusive licence to United States &amp; Canadian Academy of Pathology.</rights><rights>The Author(s), under exclusive licence to United States &amp; Canadian Academy of Pathology 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</citedby><cites>FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</cites><orcidid>0000-0001-8623-4067 ; 0000-0002-9012-6680 ; 0000-0001-6754-0480 ; 0000-0003-0217-1789 ; 0000-0002-5755-8932 ; 0000-0002-7361-7162 ; 0000-0001-9513-245X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35562413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gisriel, Savanah D.</creatorcontrib><creatorcontrib>Yuan, Ji</creatorcontrib><creatorcontrib>Braunberger, Ryan C.</creatorcontrib><creatorcontrib>Maracaja, Danielle L.V.</creatorcontrib><creatorcontrib>Chen, Xueyan</creatorcontrib><creatorcontrib>Wu, Xiaojun</creatorcontrib><creatorcontrib>McCracken, Jenna</creatorcontrib><creatorcontrib>Chen, Mingyi</creatorcontrib><creatorcontrib>Xie, Yi</creatorcontrib><creatorcontrib>Brown, Laura E.</creatorcontrib><creatorcontrib>Li, Peng</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Sethi, Tarsheen</creatorcontrib><creatorcontrib>McHenry, Austin</creatorcontrib><creatorcontrib>Hauser, Ronald G.</creatorcontrib><creatorcontrib>Paulson, Nathan</creatorcontrib><creatorcontrib>Tang, Haiming</creatorcontrib><creatorcontrib>Hsi, Eric D.</creatorcontrib><creatorcontrib>Wang, Endi</creatorcontrib><creatorcontrib>Zhang, Qian-Yun</creatorcontrib><creatorcontrib>Young, Ken H.</creatorcontrib><creatorcontrib>Xu, Mina L.</creatorcontrib><creatorcontrib>Pan, Zenggang</creatorcontrib><title>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.</description><subject>13/1</subject><subject>13/51</subject><subject>38/32</subject><subject>631/67/1990/291/1621/1915</subject><subject>692/699/1541/1990/291/1621/1915</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>B-cell lymphoma</subject><subject>Case reports</subject><subject>CD20 antigen</subject><subject>Chemotherapy</subject><subject>Effusion</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr Virus Infections - complications</subject><subject>Herpesviridae Infections - complications</subject><subject>Herpesvirus 4, Human</subject><subject>Herpesvirus 8, Human</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Primary Effusion - diagnosis</subject><subject>Lymphoma, Primary Effusion - pathology</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Myc protein</subject><subject>Pathology</subject><subject>Pax5 protein</subject><subject>Pleural cavity</subject><subject>Primary effusion lymphoma</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtv1DAUhSMEokPhD7BAltiwCdh52ghVggooUiU2sLZubm4mrhJ7sJ2hs-WX4yGlPBZdWfL9zvE9Pln2VPCXgpfyVahE2aqcF0XOBVciv76XbURd8nQl6_vZhktV5qWqi5PsUQhXnIuqlsXD7KSs66ZI6k3242KZwbKR_I7C3vglMJlb2kI0e2I0DEswzuYdBOrZBH5L7F2ONE1sOsy70c3wmgHrTYjGYmRko4kH9t3EkS3WfFuI4WSsQbeDOLrJbQ0yHMEDRvJHFYbH2YMBpkBPbs7T7OuH91_OL_LLzx8_nb-9zLEu2pgLPqQ4opEddBJlW0NVNkDUCgRVK970UgLyXkkYKqz6FlupBGAHqIam4-Vpdrb67pZuph7Trh4mvfNmBn_QDoz-d2LNqLdur5UqGlU1yeDFjYF3KVmIejbh-BdgyS1BF01TSd5IXiX0-X_olVu8TfF00QqZsFYeqWKl0LsQPA23ywiujxXrtWKdKta_KtbXSfTs7xi3kt-dJqBcgZBGdkv-z9t32r5ZVZQq2JukCmjIIvXGE0bdO3OX_CeGEMou</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Gisriel, Savanah D.</creator><creator>Yuan, Ji</creator><creator>Braunberger, Ryan C.</creator><creator>Maracaja, Danielle L.V.</creator><creator>Chen, Xueyan</creator><creator>Wu, Xiaojun</creator><creator>McCracken, Jenna</creator><creator>Chen, Mingyi</creator><creator>Xie, Yi</creator><creator>Brown, Laura E.</creator><creator>Li, Peng</creator><creator>Zhou, Yi</creator><creator>Sethi, Tarsheen</creator><creator>McHenry, Austin</creator><creator>Hauser, Ronald G.</creator><creator>Paulson, Nathan</creator><creator>Tang, Haiming</creator><creator>Hsi, Eric D.</creator><creator>Wang, Endi</creator><creator>Zhang, Qian-Yun</creator><creator>Young, Ken H.</creator><creator>Xu, Mina L.</creator><creator>Pan, Zenggang</creator><general>Elsevier Inc</general><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8623-4067</orcidid><orcidid>https://orcid.org/0000-0002-9012-6680</orcidid><orcidid>https://orcid.org/0000-0001-6754-0480</orcidid><orcidid>https://orcid.org/0000-0003-0217-1789</orcidid><orcidid>https://orcid.org/0000-0002-5755-8932</orcidid><orcidid>https://orcid.org/0000-0002-7361-7162</orcidid><orcidid>https://orcid.org/0000-0001-9513-245X</orcidid></search><sort><creationdate>20221001</creationdate><title>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</title><author>Gisriel, Savanah D. ; Yuan, Ji ; Braunberger, Ryan C. ; Maracaja, Danielle L.V. ; Chen, Xueyan ; Wu, Xiaojun ; McCracken, Jenna ; Chen, Mingyi ; Xie, Yi ; Brown, Laura E. ; Li, Peng ; Zhou, Yi ; Sethi, Tarsheen ; McHenry, Austin ; Hauser, Ronald G. ; Paulson, Nathan ; Tang, Haiming ; Hsi, Eric D. ; Wang, Endi ; Zhang, Qian-Yun ; Young, Ken H. ; Xu, Mina L. ; Pan, Zenggang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>13/1</topic><topic>13/51</topic><topic>38/32</topic><topic>631/67/1990/291/1621/1915</topic><topic>692/699/1541/1990/291/1621/1915</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>B-cell lymphoma</topic><topic>Case reports</topic><topic>CD20 antigen</topic><topic>Chemotherapy</topic><topic>Effusion</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr Virus Infections - complications</topic><topic>Herpesviridae Infections - complications</topic><topic>Herpesvirus 4, Human</topic><topic>Herpesvirus 8, Human</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Primary Effusion - diagnosis</topic><topic>Lymphoma, Primary Effusion - pathology</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Myc protein</topic><topic>Pathology</topic><topic>Pax5 protein</topic><topic>Pleural cavity</topic><topic>Primary effusion lymphoma</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gisriel, Savanah D.</creatorcontrib><creatorcontrib>Yuan, Ji</creatorcontrib><creatorcontrib>Braunberger, Ryan C.</creatorcontrib><creatorcontrib>Maracaja, Danielle L.V.</creatorcontrib><creatorcontrib>Chen, Xueyan</creatorcontrib><creatorcontrib>Wu, Xiaojun</creatorcontrib><creatorcontrib>McCracken, Jenna</creatorcontrib><creatorcontrib>Chen, Mingyi</creatorcontrib><creatorcontrib>Xie, Yi</creatorcontrib><creatorcontrib>Brown, Laura E.</creatorcontrib><creatorcontrib>Li, Peng</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Sethi, Tarsheen</creatorcontrib><creatorcontrib>McHenry, Austin</creatorcontrib><creatorcontrib>Hauser, Ronald G.</creatorcontrib><creatorcontrib>Paulson, Nathan</creatorcontrib><creatorcontrib>Tang, Haiming</creatorcontrib><creatorcontrib>Hsi, Eric D.</creatorcontrib><creatorcontrib>Wang, Endi</creatorcontrib><creatorcontrib>Zhang, Qian-Yun</creatorcontrib><creatorcontrib>Young, Ken H.</creatorcontrib><creatorcontrib>Xu, Mina L.</creatorcontrib><creatorcontrib>Pan, Zenggang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gisriel, Savanah D.</au><au>Yuan, Ji</au><au>Braunberger, Ryan C.</au><au>Maracaja, Danielle L.V.</au><au>Chen, Xueyan</au><au>Wu, Xiaojun</au><au>McCracken, Jenna</au><au>Chen, Mingyi</au><au>Xie, Yi</au><au>Brown, Laura E.</au><au>Li, Peng</au><au>Zhou, Yi</au><au>Sethi, Tarsheen</au><au>McHenry, Austin</au><au>Hauser, Ronald G.</au><au>Paulson, Nathan</au><au>Tang, Haiming</au><au>Hsi, Eric D.</au><au>Wang, Endi</au><au>Zhang, Qian-Yun</au><au>Young, Ken H.</au><au>Xu, Mina L.</au><au>Pan, Zenggang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>35</volume><issue>10</issue><spage>1411</spage><epage>1422</epage><pages>1411-1422</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><abstract>Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>35562413</pmid><doi>10.1038/s41379-022-01091-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8623-4067</orcidid><orcidid>https://orcid.org/0000-0002-9012-6680</orcidid><orcidid>https://orcid.org/0000-0001-6754-0480</orcidid><orcidid>https://orcid.org/0000-0003-0217-1789</orcidid><orcidid>https://orcid.org/0000-0002-5755-8932</orcidid><orcidid>https://orcid.org/0000-0002-7361-7162</orcidid><orcidid>https://orcid.org/0000-0001-9513-245X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0893-3952
ispartof Modern pathology, 2022-10, Vol.35 (10), p.1411-1422
issn 0893-3952
1530-0285
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9926946
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects 13/1
13/51
38/32
631/67/1990/291/1621/1915
692/699/1541/1990/291/1621/1915
Aged
Aged, 80 and over
B-cell lymphoma
Case reports
CD20 antigen
Chemotherapy
Effusion
Epstein-Barr virus
Epstein-Barr Virus Infections - complications
Herpesviridae Infections - complications
Herpesvirus 4, Human
Herpesvirus 8, Human
HIV
Human immunodeficiency virus
Humans
Laboratory Medicine
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Primary Effusion - diagnosis
Lymphoma, Primary Effusion - pathology
Medical prognosis
Medicine
Medicine & Public Health
Myc protein
Pathology
Pax5 protein
Pleural cavity
Primary effusion lymphoma
Retrospective Studies
Rituximab
Targeted cancer therapy
title Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A11%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20herpesvirus%208-negative%20effusion-based%20large%20B-cell%20lymphoma:%20a%20distinct%20entity%20with%20unique%20clinicopathologic%20characteristics&rft.jtitle=Modern%20pathology&rft.au=Gisriel,%20Savanah%20D.&rft.date=2022-10-01&rft.volume=35&rft.issue=10&rft.spage=1411&rft.epage=1422&rft.pages=1411-1422&rft.issn=0893-3952&rft.eissn=1530-0285&rft_id=info:doi/10.1038/s41379-022-01091-x&rft_dat=%3Cproquest_pubme%3E2664806804%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718480784&rft_id=info:pmid/35562413&rft_els_id=S0893395222002563&rfr_iscdi=true